Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB3 | P28472 | 3/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2772926 | 0.88 | P2RX7 (0.39) | GABRB3GABRA2GABRB2P2RX7PDE4B | |
| SCHEMBL2772997 | 0.82 | RORC (0.38) | P2RX7PDE4BSMN1; SMN2GAAPDE4A | |
| SCHEMBL2771556 | 0.80 | PDE4B (0.39) | P2RX7ALDH1A1PDE4BSMN1; SMN2GAA | |
| SCHEMBL497962 | 0.73 | GABRB3 (0.47) | GABRB3GABRA2GABRB2ALDH1A1 | |
| SCHEMBL2772721 | 0.70 | KCNJ5 (0.39) | — | |
| SCHEMBL2772572 | 0.67 | KDM4E (0.41) | ALDH1A1 | |
| SCHEMBL9174929 | 0.66 | TAAR1 (0.58) | ALDH1A1SMN1; SMN2GAAF2RL1 | |
| SCHEMBL27331166 | 0.64 | APLNR (0.36) | ALDH1A1SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL14719474 | 0.64 | TAAR1 (0.56) | ALDH1A1SMN1; SMN2GAAF2RL1 | |
| SCHEMBL497822 | 0.64 | GABRB3 (0.51) | GABRB3GABRA2GABRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846960-B2 | FXR agonists | ELI LILLY AND COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20090270460-A1 | FXR AGONISTS | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270460-A1 | FXR AGONISTS | NR1H4, SLC10A1, GPBAR1 | GABRB3 405/4885GABRA2 696/4885GABRB2 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.